🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Knowledge of #exosomes has blossomed in the 21st century, with research linking exosomes to cancer growth & #metastasis. Exosomes condition the #TumorMicroenvironment or “fertilize the soil” to enable cancer growth. More in Nature Reviews Cancer: bit.ly/3CeXEpi #Exosome101

#Exosomes do not just modify cancer cells and the #TumorMicroenvironment by releasing their contents: they also have PD-L1, an immune checkpoint protein, on their surface. #PDL1 inhibits anti-tumor immune responses. Read more in nature: bit.ly/3MiD0t0 #Exosome101

Immunome’s discovery engine interrogates human memory #BCells to see how #cancer cells look in the context of the #TumorMicroenvironment to identify #antibody-based treatments. See more on our website: bit.ly/3CjmNPB #Exosome101

Immunome’s discovery engine suggests that the human immune system is responding against cellular processes regulating membrane dynamics and #exosome formation. We look forward to understanding how targeting this process may lead to therapeutic benefit. #Exosome101

We look forward to presenting results at #SITC22. Our poster is focused on IMM20059, an #antibody that binds epsin-1 (EPN1), a novel target in the membrane dynamics/exosome target class which inhibits tumor growth. Press release here: bit.ly/3Tgi4Vi #Exosome101

We’re excited to announce our multi-year collaboration with AbbVie! Our collaboration will utilize our proprietary Discovery Engine to unlock novel #cancer biology & identify up to 10 antibody-target pairs arising from 3 specified tumor types. More here: bit.ly/3WXUMX2

We are proud to collaborate with AbbVie and look forward to utilizing our Discovery Engine to discover novel #cancer therapeutics by harnessing the power of human memory #Bcells. To learn more, visit Endpoints News: bit.ly/3Zz8wZY

We are pleased to announce the formation of our Antibody-Drug Conjugate (ADC) & T cell redirection (TCR) advisory board comprised of Drs. John Lambert and Anthony Tolcher, to prioritize selection of novel targets for ADC & TCR modalities. More here: bit.ly/3x7JyUo $IMNM

Our CTO Matthew Robinson, Ph.D., will discuss how our Discovery Engine can harness the power of human memory #Bcells to identify novel targets for development as #AntibodyDrugConjugates at the 13th Annual World ADC London conference. Read more: bit.ly/3kXLbSd

We’re delighted to be partnering with the World ADC London Summit from March 13-16, Europe’s definitive #AntibodyDrugConjugate event dedicated to maximizing the therapeutic window of ADCs. Register & use our code (30318SPN) to receive a 20% discount: bit.ly/3mGswuI

Want to learn more about how human memory #Bcells could be used to identify novel targets for development as #ADCs? Today our CTO Matthew Robinson, Ph.D., will present on our Discovery Engine at the 13th Annual World ADC London conference. Read more: bit.ly/3kXLbSd

Want to learn more about how human memory #Bcells could be used to identify novel targets for development as #ADCs? Today our CTO Matthew Robinson, Ph.D., will present on our Discovery Engine at the 13th Annual World ADC London conference. Read more: bit.ly/3kXLbSd

Our CTO Matt Robinson, Ph.D. will join colleagues in #biotech and #pharma in presenting at the 2023 SAPA-GP Conference on Saturday, April 1. Matt will introduce our human #MemoryBCell platform and how it can support #drugdevelopment. More here: bit.ly/3FZklQZ $IMNM

#ICYMI: Our CTO Matt Robinson, Ph.D. presented on our Discovery Engine’s ability to utilize human memory #Bcells to identify targets for development as #AntibodyDrugConjugates at the World ADC London conference. Learn more about our research: bit.ly/3Zq5Ts1 $IMNM

Matt Robinson, Ph.D., Immunome's CTO, was recently featured on Labiotech.eu's Beyond Biotech podcast where he spoke with Jim Cornall in depth about #ADCs and our Discovery Engine platform potential. Listen here: bit.ly/41435lL $IMNM

Exciting news! Preclinical data on our anti-IL38 program has been published in mAbs under the title "IL-38 blockade induces anti-tumor immunity by abrogating tumor-mediated suppression of early immune activation:" bit.ly/3MzHvzE $IMNM

Immunome's CTO Matt Robinson, Ph.D., was featured in a PharmaShots - Incisive news in 3 shots Q&A with Senior Editor Smriti Bhardwaj where he discussed Immunome's deal with AbbVie and the potential of our Discover Engine. Read more here: bit.ly/3HPQM5o $IMNM

Immunome’s President and CEO, Purnanand Sarma, Ph.D., & CFO Corleen Roche, were featured in BioProcess Online where they spoke in detail with Matt Deegan Pillar about Immunome's platform partnership potential & strategic collaboration with AbbVie. More here: bit.ly/459g9sz $IMNM

Immunome Senior Director of Antibody Engineering, Pavel Nikitin, Ph.D., recently facilitated a discussion on mining the antibody repertoire from tumor patients at hubXchange’s Antibody Therapeutics Xchange East Coast 2023. Read more here: bit.ly/3ow9NmN

We’re thrilled to announce we have entered a definitive merger agreement with Morphimmune! This merger will unite our technology platforms for the development of best-in-class targeted #cancer therapies across multiple modalities. More here: fal.cn/3zvsn $IMNM